New Chairman for MHRA
Stephen Lightfoot has been appointed as the Agency’s new Chair from 1st September 2020. He succeeds Prof Sir Michael Rawlins GBE, Kt who has been the Chair of the Agency Board since December 2014.
Stephen has been a Non-Executive Director of the Agency since September 2015 and is also Deputy Chair of Sussex Community NHS Foundation Trust and Non-Executive Chair of Sussex Primary Care Limited.
Before joining the Board, Stephen had a 30-year career in the life sciences industry working on the development and commercialisation of a wide range of medicines and medical devices in UK and global healthcare companies. His most recent executive roles were General Manager of the global pharmaceutical diagnostics business of GE Healthcare, Managing Director of the UK pharmaceutical business of Daiichi Sankyo and Commercial Director of the UK pharmaceutical and medical device business of Schering Healthcare.
BIVDA will be writing to Stephen when he takes up his position to outline the IVD sector's priorities for the MHRA, especially with regard to regulatory regimes post-December 31st when the transition period ends.